Management of Subtherapeutic INR in Patients on Warfarin Therapy

Assessment of Subtherapeutic INR

The American College of Chest Physicians recommends that for patients with a single out-of-range INR of ≤0.5 below therapeutic range with previously stable INRs, continue the current dose and retest within 1-2 weeks 1, 2, 3
Evidence shows that immediate dose adjustments for minor INR deviations do not improve outcomes compared to maintaining the current dose, with a strength of evidence based on observational studies 1, 2
An observational study of 3,961 patients suggested that warfarin doses do not need to be changed for INRs between 1.7 and 3.3, providing insight into the management of patients with slightly elevated INR values 2

The American College of Chest Physicians recommends continuing the current dose if INR is only slightly below therapeutic range (≤0.5 below target), based on evidence from clinical guidelines 1, 2
Schedule follow-up INR test in 1-2 weeks to ensure INR is not progressively deviating from therapeutic range, as suggested by clinical practice guidelines 3
Routine administration of heparin bridging is not recommended for patients with a single subtherapeutic INR, according to the American College of Chest Physicians 3

For patients with mechanical heart valves or other high-risk conditions with persistently low INR, more aggressive dose adjustments may be warranted, as recommended by the American Heart Association 4
Consider increasing warfarin dose to achieve higher target INR (2.5-3.5) for patients with mechanical heart valves or other high-risk conditions, based on guidelines from the American Heart Association 4

Routine bridging with heparin is not recommended for patients with a single subtherapeutic INR, as it increases bleeding risk without clear benefit, according to the American College of Chest Physicians 3
A retrospective study of 2,597 patients showed no significant difference in thromboembolic events between patients with subtherapeutic INR and those with therapeutic INR, providing evidence for the safety of omitting bridging therapy 3
Even in patients with mechanical heart valves, the incidence of thromboembolic events was only 0.4% without bridging therapy, suggesting that bridging may not be necessary in this population 3

Once stable, monitoring intervals can be extended up to 12 weeks in patients with consistently stable INRs, as recommended by clinical guidelines 5

Evidence shows that immediate dose adjustments for minor INR deviations do not improve outcomes compared to maintaining the current dose, highlighting the importance of avoiding overreaction to single subtherapeutic INR values 1, 2
Routine bridging with heparin for single subtherapeutic INR increases bleeding risk without clear benefit, and should be avoided according to the American College of Chest Physicians 3
Ensure patients understand the importance of consistent vitamin K intake and medication adherence, as recommended by clinical guidelines 3

Intercurrent illness with diarrhea or vomiting may decrease warfarin absorption, which is a critical factor to investigate in patients with subtherapeutic INR 6